We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Zinc and Copper Buildup May Cause Alzheimer's Disease

By Biotechdaily staff writers
Posted on 16 Jan 2004
By showing that a metal-protein attenuating compound (MPAC) can inhibit zinc and copper ions from binding to beta amyloid in a clinical trial and thereby treat Alzheimer's disease, a Harvard researcher has been able to provide support for his theory that chemicals are the cause of the disease. More...
The results of the trial were reported in he December 12, 2003, issue of the Archives of Neurology.

In the view of Dr. Ashley Bush, of Harvard Medical School (Boston, MA, USA), Alzheimer's disease is caused by a copper and zinc buildup in the brain. In experiments, he found that by adding zinc to dead brain tissue, the beta amyloid would form clumps resembling the plaques of Alzheimer's disease. He believes that accumulated copper and zinc mix with beta amyloid in the brains of Alzheimer's patients and oxidize, thereby destroying nerve cells. However, he has had difficulty proving this.

Following a successful mouse study that showed a 50% reduction in amyloid deposits, a small clinical trial of a drug designed to inhibit this process has shown promise as a treatment for Alzheimer's, lending credence to Dr. Bush's theory. In this trial of 32 volunteers, half received a seventy-year-old drug called clioquinol and half received placebo. Those on placebo showed a worsening of Alzheimer's, while those on the drug showed minimal deterioration. Additionally, those taking the drug had a decline of amyloid protein in their blood levels, which did not occur in those on placebo. A number of scientists are now pushing for further research on this drug or similar drugs, and large-scale clinical trials are in the planning stage at two universities.




Related Links:
Harvard Medical

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.